Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Unipolar depression in adults: Treatment with lithium

Michael Gitlin, MD
Section Editor
Peter P Roy-Byrne, MD
Deputy Editor
David Solomon, MD


Lithium is mainly used to treat bipolar disorder, which is characterized by recurrent episodes of depression, mania, and hypomania. However, lithium is also used as an adjunctive medication in patients who have inadequately responded to an antidepressant for treatment of unipolar depression (ie, depression with no lifetime history of mania or hypomania) [1]. In addition, lithium is used as monotherapy to treat acute episodes of unipolar depression and as maintenance treatment to prevent recurrence of unipolar depressive episodes.

Lithium was first used by psychiatrists in the mid-1800s [2]. The first controlled trial of lithium for unipolar depression was in 1968.

This topic reviews the use of lithium as adjunctive treatment and as monotherapy for acute episodes and maintenance treatment of unipolar depression. Treatment resistant depression and the use of lithium to treat bipolar disorder are discussed separately. (See "Unipolar depression in adults: Treatment of resistant depression" and "Bipolar disorder in adults: Pharmacotherapy for acute mania and hypomania", section on 'General principles' and "Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lithium'.)


The most common use of lithium in patients with unipolar depression is to augment an antidepressant that does not adequately treat a depressive syndrome. Lithium or an alternative adjunctive agent is often necessary because remission with antidepressant monotherapy occurs in only 28 to 47 percent of patients, even with an optimal trial [3-5]. It is commonly thought that augmentation is more effective for patients who initially have a partial response to antidepressant monotherapy, compared with patients who do not respond at all, but this is not established [6].

Efficacy — Results from many studies support using lithium for depressed patients who do not fully respond to an antidepressant [7]:


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jan 18, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Dé Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981; 138:252.
  2. Shorter E. The history of lithium therapy. Bipolar Disord 2009; 11 Suppl 2:4.
  3. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.
  4. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66:974.
  5. Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010; 25:189.
  6. Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63:826.
  7. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68:935.
  8. Nelson JC, Baumann P, Delucchi K, et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 2014; 168:269.
  9. Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015; 76:e487.
  10. Bauer M, Forsthoff A, Baethge C, et al. Lithium augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci 2003; 253:132.
  11. Bauer M, Adli M, Baethge C, et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry 2003; 48:440.
  12. Valenstein M, McCarthy JF, Austin KL, et al. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006; 163:1219.
  13. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519.
  14. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387.
  15. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002; 22:379.
  16. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994; 151:1372.
  17. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117 Suppl 1:S26.
  18. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162:634.
  19. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19:427.
  20. Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 2006; 12:2985.
  21. Bauer M, Bschor T, Kunz D, et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157:1429.
  22. Bschor T, Berghöfer A, Ströhle A, et al. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 2002; 22:427.
  23. Bauer M, Linden M, Schaaf B, Weber HJ. Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. J Clin Psychopharmacol 1996; 16:130.
  24. Hawley CJ, Loughlin PJ, Quick SJ, et al. Efficacy, safety and tolerability of combined administration of lithium and selective serotonin reuptake inhibitors: a review of the current evidence. Hertfordshire Neuroscience Research Group. Int Clin Psychopharmacol 2000; 15:197.
  25. Zusky PM, Biederman J, Rosenbaum JF, et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol 1988; 8:120.
  26. Bauer M, Adli M, Bschor T, et al. Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology 2010; 62:36.
  27. Khan MC, Wickham EA, Reed JV. Lithium versus placebo in acute depression: a clinical trial. Int Clin Psychopharmacol 1987; 2:47.
  28. Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 1991; 158:666.
  29. Linder J, Fyrö B, Pettersson U, Werner S. Acute antidepressant effect of lithium is associated with fluctuation of calcium and magnesium in plasma. A double-blind study on the antidepressant effect of lithium and clomipramine. Acta Psychiatr Scand 1989; 80:27.
  30. Mendels J, Ramsey TA, Dyson WL, Frazer A. Lithium as an antidepressant. Arch Gen Psychiatry 1979; 36:845.
  31. Bauer, M, Crossley, NA, Gerber, S, et al. The acute antidepressive effects of lithium: from monotherapy to augmentation therapy in major depression. In: Lithium in Neuropsychiatry, Bauer, et al (Eds), Informa UK Ltd, United Kingdom 2006. p.109.
  32. Bschor T, Uhr M, Baethge C, et al. Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression. J Clin Psychopharmacol 2013; 33:38.
  33. Davis, JM. Lithium maintenance of unipolar depression. In: Lithium in Neuropsychiatry: The Comprehensive Guide, Bauer, M, Grof, P, Muller-Oerlinghausen, B (Eds), Informa UK Ltd, 2006. p.99.
  34. Cipriani A, Smith K, Burgess S, et al. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev 2006; :CD003492.
  35. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder, 2nd, American Psychiatric Press, 2000